still flicker flame weaken
absenc meaning catalyst make nt recoveri unlik think
spark lack catalyst drive signific upsid back half
year think valu mostli come stock think
could vulner competitor pfizer/sangamo
present initi efficaci data clarifi valrox product
profil expect meaning new data
see possibl data dose prophi
steroid could partial de-risk phase phase data like
earli look long-term believ spk-gaa pomp
program could attract new investor move clinic
timelin pipelin program see limit valu
expect fairli mute choroideremia updat
expect spk-gaa pomp enter clinic earli
current pipelin program
model chang lower lt peak market share hem
gene therapi think efficaci first mover durabl
influenc market share reflect less differenti product profil
consid data date gene therapi remain hot area
expect today data lead modest leakag spark premium
reduc npv weight
valuat downgrad under-perform lower tp
risk tp rate includ failur clinic trial
competitor better expect preclinical/earli data pipelin
valuat metric
number share
rate outperform under-perform
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
spark biotechnolog compani focus
develop commerci gene therapi treatment
price aug rate outperform under-perform target price analyst
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
de-risk favor profil increas
program po long-term market share
increas platform/technolog valu
increas valu pomp program
fail develop/identifi competit product profil spk-
lose pipeline/technolog valu face
reimburs challeng luxturna
 close
compani mention price
